公开(公告)号：US20220401443A1

公开(公告)日：2022-12-22

申请号：US17866203

申请日：2022-07-15

申请人： Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

发明人： Vijaykumar Reddy RAJASEKHAR ,  Brendan Mark JOHNSON ,  David B. MACLEAN ,  Lynn SEELY ,  Paul N. MUDD, JR.

IPC分类号： A61K31/501 ,  A61P35/00 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

摘要： Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240358700A1

公开(公告)日：2024-10-31

申请号：US18758904

申请日：2024-06-28

申请人： Sumitomo Pharma Switzerland GmbH ,  Takeda Pharmaceutical Company Limited

发明人： Vijaykumar Reddy RAJASEKHAR ,  Brendan Mark JONHSON ,  David B. MACLEAN ,  Lynn SEELY ,  Paul N. MUDD, JR. ,  Hélène M. FAESSEL

IPC分类号： A61K31/501 ,  A61K9/00 ,  A61K31/4166 ,  A61K31/513 ,  A61P35/00

CPC分类号： A61K31/501 ,  A61K9/0053 ,  A61K31/4166 ,  A61K31/513 ,  A61P35/00

摘要： Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.